Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology.
Level 5 - mechanism / opinion, no new human data
Expert consensus statement and narrative clinical guidance without original empirical data or formal systematic review
PubMed 42132708 · doi:10.1016/j.ophtha.2026.04.008
What was done
The North American Neuro-Ophthalmology Society (NANOS) and the American Academy of Ophthalmology (AAO) developed a joint consensus statement to provide clinical guidance on the potential association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs, such as semaglutide) and non-arteritic anterior ischemic optic neuropathy (NAION) based on an assessment of currently available retrospective observational studies, electronic health record analyses, and claims data.
What was found
The abstract reports no quantitative values or effect estimates. It notes that while many retrospective observational studies report a small possible increased risk of NAION in patients taking GLP-1 RAs, other studies find no correlation. The overall magnitude of NAION risk is described as low. The societies recommend shared decision-making between patients and their healthcare providers regarding starting, continuing, or stopping GLP-1 RAs.
Why it matters
This consensus statement provides formal clinical guidance from major neuro-ophthalmology and ophthalmology organizations to address growing clinical concerns regarding GLP-1 RA-associated optic nerve toxicity.
Limits
The guidance relies on retrospective observational and administrative claims data with inherent methodological limitations, potential confounding, and conflicting findings. No prospective, randomized, or quantitative risk data are provided in the abstract.
Cited by
- partial Stroke of the eye (non-arteritic anterior ischemic optic neuropathy) is becoming more prevalent due to Ozempic and other GLP-1 weight loss drugs, affecting approximately 30,000 people annually in the United States.